JAGX - Jaguar Health, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Francisco,
United States
Type: Equity
JAGX price evolution
JAGX
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.23 | $8.63 | $14.37 | $5.47 |
| Short term investments | ||||
| Net receivables | $1.84 | $1.56 | $1.44 | $2.47 |
| Inventory | $8.38 | $8.26 | $8.68 | $7.02 |
| Total current assets | $22.06 | $28.23 | $32.36 | $22.32 |
| Long term investments | ||||
| Property, plant & equipment | $1.33 | $1.47 | $1.6 | $1.7 |
| Goodwill & intangible assets | $20.97 | $21.46 | $21.95 | $22.44 |
| Total noncurrent assets | $23.32 | $23.95 | $24.57 | $25.13 |
| Total investments | ||||
| Total assets | $45.38 | $52.17 | $56.93 | $47.45 |
| Current liabilities | ||||
| Accounts payable | $5.13 | $4.66 | $5.69 | $5.81 |
| Deferred revenue | ||||
| Short long term debt | $4.04 | $14.32 | $16.12 | $16.37 |
| Total current liabilities | $12.46 | $29 | $31.1 | $30.34 |
| Long term debt | $31.51 | $17.34 | $18.17 | $17.74 |
| Total noncurrent liabilities | $31.51 | $17.34 | $18.17 | $18.47 |
| Total debt | $35.54 | $31.66 | $34.3 | $34.84 |
| Total liabilities | $43.96 | $46.34 | $49.27 | $48.11 |
| Shareholders' equity | ||||
| Retained earnings | -$299.08 | -$291.3 | -$279.15 | -$266.95 |
| Other shareholder equity | -$0.8 | -$0.72 | -$0.88 | -$0.68 |
| Total shareholder equity | $1.36 | $5.64 | $7.35 | -$0.66 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.47 | $17.05 | $8.09 | $3.88 |
| Short term investments | ||||
| Net receivables | $2.47 | $2.14 | $4.56 | $1.69 |
| Inventory | $7.02 | $4.9 | $2.78 | $2.13 |
| Total current assets | $22.32 | $28.43 | $17.79 | $9.52 |
| Long term investments | ||||
| Property, plant & equipment | $1.7 | $1.73 | $0.68 | $1.26 |
| Goodwill & intangible assets | $22.44 | $22.65 | $24.34 | $26.02 |
| Total noncurrent assets | $25.13 | $24.83 | $25.05 | $26.89 |
| Total investments | ||||
| Total assets | $47.45 | $53.27 | $42.84 | $36.41 |
| Current liabilities | ||||
| Accounts payable | $5.81 | $4.93 | $4.76 | $5.35 |
| Deferred revenue | ||||
| Short long term debt | $16.37 | $3.42 | $3.79 | $7.12 |
| Total current liabilities | $30.34 | $15.47 | $13.22 | $15.39 |
| Long term debt | $17.74 | $25.94 | $12.42 | $0.45 |
| Total noncurrent liabilities | $18.47 | $25.94 | $12.42 | $0.45 |
| Total debt | $34.84 | $29.36 | $16.21 | $7.57 |
| Total liabilities | $48.11 | $41.41 | $25.64 | $15.84 |
| Shareholders' equity | ||||
| Retained earnings | -$266.95 | -$219.49 | -$166.9 | -$133.09 |
| Other shareholder equity | -$0.68 | $11.61 | ||
| Total shareholder equity | -$0.66 | $11.61 | $17.2 | $10.67 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.81 | $2.68 | $1.97 | $3.26 |
| Cost of revenue | $0.51 | $0.49 | $0.34 | $0.49 |
| Gross Profit | $2.3 | $2.19 | $1.63 | $2.77 |
| Operating activities | ||||
| Research & development | $6.08 | $4.28 | $4.78 | $4.31 |
| Selling, general & administrative | $5 | $6.01 | $6.7 | $4.74 |
| Total operating expenses | $11.16 | $10.29 | $11.47 | $9.05 |
| Operating income | -$8.86 | -$8.1 | -$9.85 | -$6.29 |
| Income from continuing operations | ||||
| EBIT | -$7.28 | -$8.7 | -$10.02 | -$4.66 |
| Income tax expense | ||||
| Interest expense | $0.5 | $3.45 | $2.18 | $2.63 |
| Net income | ||||
| Net income | -$7.78 | -$12.15 | -$12.2 | -$7.29 |
| Income (for common shares) | -$7.78 | -$12.15 | -$12.2 | -$7.58 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11.96 | $4.33 | $9.38 | $5.78 |
| Cost of revenue | $2.02 | $2.33 | $3.28 | $3.82 |
| Gross Profit | $9.94 | $2 | $6.11 | $1.96 |
| Operating activities | ||||
| Research & development | $17.65 | $15.08 | $6.41 | $5.82 |
| Selling, general & administrative | $26.7 | $26 | $21 | $20.44 |
| Total operating expenses | $44.35 | $42.71 | $32.75 | $30.91 |
| Operating income | -$34.41 | -$40.71 | -$26.65 | -$28.95 |
| Income from continuing operations | ||||
| EBIT | -$34.73 | -$44.18 | -$31.02 | -$32.8 |
| Income tax expense | $0.01 | |||
| Interest expense | $12.72 | $8.42 | $2.79 | $5.73 |
| Net income | ||||
| Net income | -$47.45 | -$52.6 | -$33.81 | -$38.54 |
| Income (for common shares) | -$47.45 | -$52.59 | -$38.65 | -$44.73 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Net income | -$7.78 | -$12.15 | -$12.2 | -$7.29 |
| Operating activities | ||||
| Depreciation | $0.63 | $0.62 | $0.55 | $0.6 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.53 | $0.53 | $0.48 | $0.4 |
| Total cash flows from operations | -$6.79 | -$9.06 | -$9.95 | -$6.42 |
| Investing activities | ||||
| Capital expenditures | -$1.6 | |||
| Investments | ||||
| Total cash flows from investing | -$0.36 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.66 | $1.55 | $17.86 | $2.68 |
| Net borrowings | -$0.06 | -$0.29 | -$1.04 | |
| Total cash flows from financing | $1.41 | $3.36 | $18.81 | $1.64 |
| Effect of exchange rate | -$0.02 | -$0.04 | $0.03 | $0.05 |
| Change in cash and equivalents | -$5.4 | -$5.74 | $8.9 | -$5.09 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$47.45 | -$52.6 | -$33.81 | -$38.54 |
| Operating activities | ||||
| Depreciation | $2.29 | $1.81 | $2.28 | $1.93 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.32 | $3.97 | $3.81 | $3.13 |
| Total cash flows from operations | -$33.1 | -$34.97 | -$15.28 | -$20.46 |
| Investing activities | ||||
| Capital expenditures | -$1.68 | -$0.01 | -$0.01 | |
| Investments | ||||
| Total cash flows from investing | -$1.68 | -$0.01 | -$0.01 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $20.46 | $35.62 | $7.76 | $6.63 |
| Net borrowings | $2.72 | $8.11 | $12.06 | -$0.1 |
| Total cash flows from financing | $23.18 | $43.94 | $19.49 | $21.77 |
| Effect of exchange rate | $0.02 | |||
| Change in cash and equivalents | -$11.58 | $8.96 | $4.21 | $1.32 |
News
Fundamentals
| Market cap | $8.69M |
|---|---|
| Enterprise value | $41.00M |
| Shares outstanding | 24.82M |
| Revenue | $10.72M |
|---|---|
| EBITDA | -$28.25M |
| EBIT | -$30.65M |
| Net Income | -$39.42M |
| Revenue Q/Q | -10.70% |
| Revenue Y/Y | -0.51% |
| P/E ratio | -0.22 |
|---|---|
| EV/Sales | 3.82 |
| EV/EBITDA | -1.45 |
| EV/EBIT | -1.34 |
| P/S ratio | 0.81 |
| P/B ratio | 4.03 |
| Book/Share | 0.09 |
| Cash/Share | 0.13 |
| EPS | -$1.59 |
|---|---|
| ROA | -78.09% |
| ROE | -1.15K% |
| Debt/Equity | -73.23 |
|---|---|
| Net debt/EBITDA | -1.44 |
| Current ratio | 1.77 |
| Quick ratio | 1.10 |